Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 18:11:1951.
doi: 10.3389/fimmu.2020.01951. eCollection 2020.

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Affiliations
Review

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Anna Vaisman-Mentesh et al. Front Immunol. .

Abstract

Monoclonal antibodies (mAbs) are a crucial asset for human health and modern medicine, however, the repeated administration of mAbs can be highly immunogenic. Drug immunogenicity manifests in the generation of anti-drug antibodies (ADAs), and some mAbs show immunogenicity in up to 70% of patients. ADAs can alter a drug's pharmacokinetic and pharmacodynamic properties, reducing drug efficacy. In more severe cases, ADAs can neutralize the drug's therapeutic effects or cause severe adverse events to the patient. While some contributing factors to ADA formation are known, the molecular mechanisms of how therapeutic mAbs elicit ADAs are not completely clear. Accurate ADA detection is necessary to provide clinicians with sufficient information for patient monitoring and clinical intervention. However, ADA assays present unique challenges because both the analyte and antigen are antibodies, so most assays are cumbersome, costly, time consuming, and lack standardization. This review will discuss aspects related to ADA formation following mAb drug administration. First, we will provide an overview of the prevalence of ADA formation and the available diagnostic tools for their detection. Next, we will review studies that support possible molecular mechanisms causing the formation of ADA. Finally, we will summarize recent approaches used to decrease the propensity of mAbs to induce ADAs.

Keywords: anti-drug antibodies; immune response; immunogenicity; monoclonal antibodies; neutralizing antibodies.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Possible causes of ADA formation. (A) Patient related and (B) drug related.
FIGURE 2
FIGURE 2
Factors that affect ADA detection in immunoassays. The center of the figure designates the components that could interfere with ADA detection (i.e., mAb, target, ADA, and secondary antibody). The middle circle designates the type of interference, while the outer circle provides examples of such interferences.

References

    1. Chan JCN, Chan ATC. Biologics and biosimilars: what, why and how? ESMO Open. (2017) 2:e000180 10.1136/esmoopen-2017-000180 - DOI
    1. Aggarwal RS. What’s fueling the biotech engine-2012 to 2013. Nat Biotechnol. (2014) 32:32–9. 10.1038/nbt.2794 - DOI - PubMed
    1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. (2015) 7:9–14. 10.4161/19420862.2015.989042 - DOI - PMC - PubMed
    1. Grilo AL, Mantalaris A. The increasingly human and profitable monoclonal antibody market. Trends Biotechnol. (2019) 37:9–16. 10.1016/j.tibtech.2018.05.014 - DOI - PubMed
    1. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine / paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytot. Cancer Res. (2001) 61:5137–44. - PubMed

Publication types

MeSH terms